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GORAB Missense Mutations Disrupt RAB6 and ARF5
Binding and Golgi Targeting
Johannes Egerer1,2,8, Denise Emmerich1,2,8, Björn Fischer-Zirnsak1,2, Wing Lee Chan1,2,
David Meierhofer3, Beyhan Tuysuz4, Katrin Marschner1, Sascha Sauer5, Francis A. Barr6, Stefan Mundlos1,2,7
and Uwe Kornak1,2,7
Gerodermia osteodysplastica is a hereditary segmental progeroid disorder affecting skin, connective tissues, and
bone that is caused by loss-of-function mutations in GORAB. The golgin, RAB6-interacting (GORAB) protein
localizes to the Golgi apparatus and interacts with the small GTPase RAB6. In this study, we used different
approaches to shed more light on the recruitment of GORAB to this compartment. We show that GORAB best
colocalizes with trans-Golgi markers and is rapidly displaced upon Brefeldin A exposition, indicating a loose
association with Golgi membranes. A yeast two-hybrid screening revealed a speciﬁc interaction with the small
GTPase ADP-ribosylation factor (ARF5) in its active, GTP-bound form. ARF5 and RAB6 bind to GORAB via the
same internal Golgi-targeting RAB6 and ARF5 binding (IGRAB) domain. Two GORAB missense mutations
identiﬁed in gerodermia osteodysplastica patients fall within this IGRAB domain. GORAB carrying the mutation p.
Ala220Pro had a cytoplasmic distribution and failed to interact with both RAB6 and ARF5. In contrast, the p.
Ser175Phe mutation displaced GORAB from the Golgi compartment to vesicular structures and selectively
impaired ARF5 binding. Our ﬁndings indicate that the IGRAB domain is crucial for the Golgi localization of
GORAB and that loss of this localization impairs its physiological function.
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INTRODUCTION
Loss-of-function mutations in golgin, Ras-related in brain 6
(RAB6)-interacting (GORAB; also named SCYL1-binding
protein 1 or NTKL-binding protein 1) cause the autosomal
recessively inherited disease gerodermia osteodysplastica
(GO, OMIM 231070; Hennies et al., 2008). Patients suffer
from lax, wrinkly skin with abnormal dermal elastic ﬁbers,
malar hypoplasia, and osteoporosis leading to increased bone
fragility. As these clinical features are reminiscent of changes
observed during human aging, GO is regarded as a segmental
progeroid disorder (Martin and Oshima, 2000). GORAB is
predicted to have two coiled-coil domains, and it resides in
the Golgi compartment, where it interacts with the guanosine
triphosphate (GTP)-bound form of the small Ras-like GTPase
RAB6 (Hennies et al., 2008), suggesting that it belongs to
the family of golgin proteins that have different roles in
Golgi-related transport processes. In addition, a cytosolic and
nuclear localization of GORAB and an interaction with the
proteins SCYL1, MDM2, and PIRH2 have been described
(Di et al., 2003; Zhang et al., 2005; Yan et al., 2010).
However, the exact physiological function of GORAB that is
disturbed in GO remains largely unknown.
The Golgi apparatus is the central hub of intracellular
membrane trafﬁcking. In mammalian cells, it is a membra-
nous organelle composed of stacked cisternae linked into
ribbons (Palade, 1975). After their synthesis, new proteins
destined for the plasma membrane or for secretion pass
through this compartment and are post-translationally
modiﬁed, sorted, and transported by membranous carriers
that bud from the Golgi membranes (Dunphy et al., 1981;
Rothman et al., 1982). Important players in Golgi function
and transport are the small Ras-like GTPases of the RAB, ADP-
ribosylation factor (ARF), and ADP-ribosylation factor-like
families. They are molecular switches, which are membrane
associated when in their active, GTP-bound conformation.
When activated, they recruit effector proteins that modify
membrane lipids, assist in cargo recruitment, guide vesicle
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budding, vesicle tethering, and fusion. Hence, small GTPases
help to give a unique identity to the membrane of the
subcompartment they localize to (Pfeffer, 2001; Zerial and
McBride, 2001; Gillingham and Munro, 2007; Barr, 2013).
The golgins are a heterogeneous group of proteins localized at
the Golgi apparatus interacting with small GTPases of the
RAB, ARF, and ADP-ribosylation factor-like families (Barr and
Short, 2003). Golgins extend from the cytosolic face of Golgi
membranes as rod-like structures with coiled-coils and are
involved in vesicle trafﬁcking, but they are also essential for
Golgi integrity and homeostasis (Behnia and Munro, 2005;
Short et al., 2005). The GORAB interaction partner RAB6 is
known to be involved in several important events of
retrograde trafﬁcking, suggesting that also GORAB might
have a related function (Mallard et al., 2002; Short et al.,
2002; Starr et al., 2010).
In this study, we speciﬁed the subcellular localization
of GORAB and identiﬁed the small GTPase ARF5 as a
previously unreported binding partner. We furthermore
mapped down the region of GORAB responsible for
interaction with the two small GTPases RAB6 and ARF5 and
for Golgi targeting. We showed that two GORAB missense
mutations within this targeting domain found in GO impaired
interaction with both GTPases and Golgi localization to
different degrees.
RESULTS
GORAB localizes to the trans-Golgi
In cell types relevant for the GO phenotype, a strong Golgi
localization of GORAB is evident (Supplementary Figure S1
online). To better understand GORAB’s function, we wanted
to investigate this subcellular localization in more detail.
Nocodazole disassembles the microtubule network and leads
to fragmentation of the Golgi apparatus into so-called
ministacks (Rogalski and Singer, 1984), making it easier to
discern spatial relation of different Golgi markers. After
Nocodazole treatment of HeLa cells and human skin
ﬁbroblasts, GORAB showed a clear separation from the cis-
Golgi marker GM130 (Nakamura et al., 1995; Figure 1a and
b). In contrast, the trans-Golgi network marker TGN46
(Prescott et al., 1997) and GORAB strongly overlapped. The
best colocalization was observable for p230 (Gleeson et al.,
1996), indicating that GORAB is localized mainly in the trans-
Golgi. Our previous studies showed that loss of GORAB did
not inﬂuence the kinetics of Brefeldin A (BFA)-induced Golgi
disassembly, but the behavior of GORAB itself in cells treated
with BFA has not yet been examined (Fischer et al., 2012).
This drug locks the small GTPase ARF1 in a complex with
its guanosine nucleotide exchange factor disrupting
endoplasmic reticulum (ER)–Golgi transport (Liang et al.,
1997; Sciaky et al., 1997). After BFA treatment, Golgi matrix
proteins such as GM130 are found at distinct ER-exit sites
(Golgi haze), whereas more loosely associated proteins such
as the Golgi SNARE GS15 are found diffusely in the ER lumen
(Lippincott-Schwartz et al., 1989). As expected, application of
BFA instantaneously disrupted the formation of the coat
protein complex 1 (COPI) coatomer (Klausner et al., 1992)
within 5minutes (Figure 1c). GM130 stayed at the Golgi
and became redistributed to ER-exit sites after 15minutes
(Figure 1c). The Golgi SNARE GS15 and GORAB showed a
reduced Golgi signal after 5 minutes of BFA treatment and a
complete redistribution to the ER after 15minutes. These
results indicate that, unlike a Golgi matrix protein, GORAB
seems only loosely associated with membranes of the trans-
Golgi network.
RAB6 interacts with the central amino acids 99 to 277 of
GORAB
In our initial studies, we showed that GORAB interacts
speciﬁcally with the constitutively active form of RAB6
(RAB6 p.Gln72Ala) but not the GDP-locked inactive form
(RAB6 p.Thr27Asn) and that GORAB colocalizes with RAB6 at
the Golgi apparatus (Hennies et al., 2008). Here we wanted to
further map the interaction domain of RAB6 on GORAB. First,
we speciﬁed the protein sequence of human GORAB, which,
in contrast to all other species except primates, possesses two
possible start methionines giving rise to proteins with a length
of 369 amino acids (aas) or 394 aas, respectively. As a
mutation of the downstream methionine codon found in GO
leads to a complete loss of GORAB expression, it is likely that
this second methionine is the main translation start
(Hennies et al., 2008). To further prove this, we analyzed
immunoprecipitated endogenous GORAB from HeLa cells by
mass spectrometry. 11 unique peptides for GORAB were
identiﬁed, among them an N-terminally acetylated peptide
starting with the alanine following the second start methionine
(Supplementary Figure S2a; Supplementary Table 1 online).
The extra 25 aas at the N terminus of the proposed 394 aa
protein were not detected. Immunoblots revealed no correlation
between GORAB band size and the presence or absence of the
upstream 25 aa reading frame in cells from different species
(Supplementary Figure S2b online). As these data corroborate
that the 369 aa variant is functionally most relevant, all cDNA
and aa positions mentioned in this study refer to this protein.
For yeast 2-hybrid (Y2H) interaction, we used three
different fragments dividing GORAB into the N-terminal aas
1 to 277, C-terminal aas 278 to 369, and the central aas 99 to
277 as prey (Figure 2a). Only yeast transformed with the
active form of RAB6 and the N-terminal aas 1 to 277 or the
central aas 99 to 277 of GORAB showed growth on selective
medium (Figure 2b). Furthermore, we performed in vitro
pulldown assays using GTP-loaded wild-type RAB6 and the
GDP-locked RAB6 mutant (p.Thr27Asn) as baits and FLAG-
tagged GORAB fragments overexpressed in HeLa cells as
prey. In contrast to full-length GORAB, neither the N terminus
nor the C terminus of GORAB were able to interact with any
form of RAB6 (Figure 2c,d, and f). The protein fragment
containing aas 99 to 277, however, interacted speciﬁcally
with wild-type GTP-bound RAB6, but not with inactive RAB6
p.Thr27Asn (Figure 2e).
ARF5 is a GORAB interaction partner and binds to the IGRAB
domain
Many golgins bind several small GTPases (Burguete et al.,
2008; Sinka et al., 2008; Hayes et al., 2009). We therefore
expanded our search for new interaction partners using a Y2H
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interaction study with all 19 known human ARF and ADP-
ribosylation factor-like family members (Figure 3a and not
shown). ARF5, one of the two class II ADP-ribosylation factors
(Volpicelli-Daley et al., 2005), was the only candidate
showing growth. This result was veriﬁed by in vitro
pulldown assays using glutathione S-transferase-tagged
ARF5 p.Gln71Leu (GTP-locked), ARF5 loaded with GDP,
and GTP-locked ARF4 p.Gln71Leu in order to prove
speciﬁcity (Figure 3b). When incubated with HeLa lysates,
only active ARF5 precipitated endogenous GORAB. Costain-
ing of endogenous GORAB and overexpressed green ﬂuor-
escent protein-tagged ARF5 p.Gln71Leu in HeLa cells
conﬁrmed colocalization of GORAB and ARF5 at the Golgi
apparatus (Figure 3c).
We performed a Y2H experiment using the different
GORAB fragments mentioned above as prey constructs and
wild-type ARF5 as bait (Figure 3d). Only yeast transformed
with ARF5 and GORAB 99–277 or GORAB 1–277 constructs
grew, implying that aas 99 to 277 sufﬁce for interaction. For
veriﬁcation of this result, we performed in vitro pulldown
assays showing that ARF5 p.Gln71Leu and wild-type ARF5
loaded with GTP interacted with FLAG-tagged GORAB,
whereas ARF5 loaded with GDP did not (Figure 3e). For the
in vitro mapping, we used GTP- and GDP-loaded wild-type
ARF5 protein and incubated them with lysates from HeLa
cells transfected with different GORAB fragments. ARF5 was
only able to bind to aas 99 to 277, but not to the N or C
terminus (Figure 3f–h), indicating that the two small GTPases
RAB6 and ARF5 both bind in the region containing aas 99 to
277. We termed this highly conserved region (Supplementary
Figure S3 online) internal Golgi-targeting Rab6 and Arf5
binding domain (IGRAB) domain.
The central aas 200–277 of GORAB are the minimum
requirement for Golgi targeting
As both small GTPases that we identiﬁed as interaction
partners for GORAB localize at the Golgi apparatus and bind
to the same IGRAB domain, we assumed that Golgi targeting
is mediated by this part of the protein. To prove this, we
analyzed the subcellular localization of the different GORAB
fragments. It should be noted that overexpression of full-
length GORAB frequently leads to the formation of ﬁbrous
structures that are not coincident with the Golgi apparatus in a
dose-dependent manner (Supplementary Figure S4a online).
These ﬁbrous aggregates were not positive for any Golgi, ER,
microtubule, or mitochondrial markers tested, but they
contain the intermediate ﬁlament vimentin, suggesting an
unspeciﬁc recruitment of coiled-coil domain proteins
(Supplementary Figure S4b online). Therefore, only cells with
a low expression level were chosen in experiments involving
transient transfection. The N- and the C-terminal parts of
GORAB were found in the cytoplasm (Figure 4). Only aas 99
to 277 showed a clear localization in a juxtanuclear position,
which coincided with staining for the Golgi marker GM130
(Figure 4). Cutting the interacting fragment between the
putative ﬁrst and second coiled-coil domains resulted in the
fragments 99–199 and 200–277, respectively. Transfection
into HeLa cells showed that only the 200–277 fragment
weakly targets to the Golgi (Figure 4). Using these fragments
in pulldown assays was not feasible owing to protein
instability (data not shown).
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Figure 1. Golgin, RAB6-interacting (GORAB) localizes at the trans-Golgi and is redistributed to the ER by Brefeldin A treatment. (a) HeLa cells or (b) human
skin ﬁbroblasts were treated for 3 h with 33 μM Nocodazole to produce Golgi ministacks. Costaining for GORAB (red), and the subcellular markers
GM130 (cis-Golgi), p230 (trans-Golgi), and TGN46 (trans-Golgi network; green) show best overlap of GORAB with the trans-Golgi markers. Lower images
show magniﬁcation of area marked by white boxes. White bars indicate areas of confocal colocalization measurements shown in the lowest panel. Traces
evaluate the degree of colocalization. (c) HeLa cells were treated for the indicated times with 5 μgml−1 Brefeldin A blocking ER-Golgi transport. GORAB (green)
was costained with COPI component δCOP, Golgi matrix protein GM130, and Golgi SNARE GS15 (all in red), respectively, by immunoﬂuorescence to
monitor the response to the treatment. Scale bars= 10 μm.
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Missense mutations in the IGRAB domain disturb ARF5 and
RAB6 binding and Golgi targeting
Previously, a p.Ala220Pro missense mutation affecting a
highly conserved residue within the minimal (aa 200–277)
targeting region of the IGRAB domain (Supplementary Figure
S3 online) was described in patients with GO (Al-Dosari and
Alkuraya, 2009). In silico analysis of GORAB predicted three
coiled-coil regions (aa 130–170, aa 200–250, and aa 270–
300) and a reduction of the probability for the aa 200–250
coil from 30% to nearly 0% in GORAB p.Ala220Pro
(Supplementary Figure S5a, b online). As no primary cells
from a patient carrying the p.Ala220Pro mutation were
available, the mutant protein was expressed in HeLa cells.
GORAB p.Ala220Pro showed an even distribution throughout
the cytoplasm (Figure 5a). Furthermore, we examined the
interaction of the protein variant with the active and inactive
forms of RAB6 and ARF5 in in vitro pulldown assays. Cell
lysates from GORAB p.Ala220Pro expressing transfected
HeLa were used, which showed high expression levels
indicating that the protein was stable (Figure 5b and c).
Interestingly, we saw only very weak interaction with both
small GTPases (Figure 5b and c), which was corroborated by
densitometric quantiﬁcation (Supplementary Figure S6a
online). In summary, this GORAB variant is neither able to
bind RAB6 nor ARF5 and is not targeted to the Golgi
apparatus.
The mutation p.Ser175Phe also introduces an exchange of
a conserved aa within the IGRAB domain, but outside the
minimum Golgi-targeting fragment 200–277 (Gardeitchik
et al., 2014). Depending on the algorithm, the mutation is
predicted to reduce the probability for the ﬁrst coiled-coil
below the threshold of 50% (Supplementary Figure S5a,b
online). Immunoﬂuorescence staining of GORAB and GM130
in skin ﬁbroblasts from a patient homozygous for this
mutation revealed a complete mislocalization of GORAB to
vesicular structures (Figure 5d). The same was observed in
HeLa cells transiently transfected with the mutant construct
(Supplementary Figure S6b online). GORAB protein levels
were not signiﬁcantly reduced in ﬁbroblasts from the patient
compared with healthy donors (Supplementary Figure S6c
online). In pulldown assays, no signiﬁcant changes in binding
to GTP-loaded RAB6 were noted (Figure 5e,Supplementary
Figure S6a online). However, the active forms of ARF5 bound
GORAB p.Ser175Phe with much lower efﬁciency (Figure 5f,
Supplementary Figure S6a online) compared with wild-type
GORAB (Figure 3b and d). To prove that loss of ARF5 and
RAB6 binding is sufﬁcient to impair GORAB Golgi targeting,
we knocked down both proteins by speciﬁc siRNAs
(Supplementary Figure S7 online). Loss of both proteins
signiﬁcantly reduced GORAB Golgi staining, albeit the effect
was more pronounced for RAB6.
DISCUSSION
In this study, we examined the subcellular localization of
GORAB, its dependency on interaction partners, and the
effect of GORAB missense mutations on protein interaction
and distribution. Although we previously described a Golgi
localization of GORAB in primary human ﬁbroblasts and
HeLa cells (Hennies et al., 2008), other studies reported a
localization of GORAB in the cytoplasm of SMMC-7721
hepatoma cells (Di et al., 2003) or in the nucleus in neuronal
PC12 cells (Liu et al., 2012), thus implying possible cell type-
dependent differences. However, in the cell types most likely
affected in GO, dermal ﬁbroblasts, and osteoblasts, GORAB
has an almost exclusive Golgi localization under normal
culturing conditions. In our hands, colocalization studies
under different Golgi disrupting conditions implied a locali-
zation of GORAB mainly in the trans-Golgi, which has a
central role in the terminal modiﬁcation of N-glycans by the
addition of sialic acid and galactose. Interestingly, loss of the
trans-Golgi-localized V-type H+-ATPase subunit a2 leads not
only to an N- and O-glycosylation defect but also to wrinkly
skin syndrome (ARCL2A), which can be misdiagnosed as GO
(Al-Gazali et al., 2001; Kornak et al., 2008; Fischer et al.,
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Figure 2. Golgin, RAB6-interacting (GORAB) interacts with RAB6 by amino
acids 99 to 277. (a) GORAB Fragments used for the mapping of interactions.
(b) Yeast 2-hybrid mapping of the interaction between active RAB6 p.
Gln72Ala as bait and the indicated fragments of GORAB as prey. Growth
control shows the presence of bait and prey constructs in the selected clones.
Growth on selective plates shows interaction of bait and prey fusion proteins.
(c–f) For in vitro pulldown experiments, wild-type, guanosine triphosphate
(GTP)-loaded RAB6 (RAB6 GTP) or inactive RAB6 p.Thr27Asn (RAB6 n.act.)
were expressed as glutathione S-transferase (GST) fusion proteins and
incubated with lysates from HeLa cells transiently transfected with the
indicated FLAG-tagged GORAB fragments. The bound protein was analyzed
on western blot with a FLAG-speciﬁc antibody. CC, coiled-coil.
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2012). However, GO patients do not display altered serum
protein glycosylation patterns, indicating that GORAB is not
crucial for glycosylation processes, at least in hepatocytes
(Hennies et al., 2008).
GORAB was initially discovered as an interaction partner of
the kinase-like protein SCYL1 (thus GORAB’s former names
SCYL1BP1 or NTKL-BP1; Di et al., 2003). However, loss-of-
function mutations in murine Scyl1 cause a neuromuscular
phenotype not overlapping with GO (Schmidt et al., 2007),
making a close functional relationship between both proteins
unlikely. It was shown that SCYL1 is involved in COPI
retrograde Golgi-to-ER trafﬁcking and maintenance of Golgi
morphology (Burman et al., 2008, 2010). In this study, we
identiﬁed ARF5 as an additional interaction partner of
GORAB by Y2H and pulldown assays. In addition, ARF5 is
found on COPI vesicles and might have a role in COPI vesicle
coat formation (Popoff et al., 2011). GORAB does not,
however, colocalize with COPI vesicles in HeLa cells under
normal conditions, nor is it found in lysates of ARF5-positive
COPI vesicles isolated from rat livers (Popoff V., personal
communication). It was described that ARF5 is also involved
in clathrin-mediated endocytosis of β1 integrin, but not the
uptake of transferrin (Moravec et al., 2012; Volpicelli-Daley
et al., 2005), suggesting a more ubiquitous distribution of
ARF5 throughout the intracellular trafﬁcking pathway. RAB6
is one of the best-studied RAB-GTPases, and it is involved
in several intracellular trafﬁcking events, for example,
endosome-to-Golgi trafﬁcking (Mallard et al., 2002).
However, the trans-Golgi is also a crucial sorting platform
for anterograde transport, and another trans-Golgi RAB6-
interacting golgin, PIST (GOP/C), has been shown to inﬂuence
the transport of several plasma membrane proteins (Cheng
et al., 2002; Wente et al., 2005).
Additional interaction partners of GORAB described in
literature are the two ubiquitin ligases, MDM2 and PIRH2
(Zhang et al., 2005; Yan et al., 2010), that localize to the
nucleus or to the nucleus and the cytoplasm, respectively. It
cannot be excluded that GORAB might also reach the nucleus
in some cell types as described for neuronal PC12 cells (Liu
et al., 2012). A factor that might inﬂuence localization and
protein–protein interaction is the GORAB N terminus.
Western blotting revealed two bands in HeLa and HAF
whose size could correspond to the 369 aa and 394 aa forms,
respectively. However, no fragments representing the
predicted 25 upstream GORAB aas were identiﬁed by mass
spectrometry, and acetylation of the penultimate alanine
residue of the 369 aa form is a typical sign for an aa at the
N-terminal end (Helbig et al., 2010). Similar data can also be
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found in Proteomics DB. We conclude that in the human cell
types that we tested, mainly the short 369 aa form is
expressed. The higher bands detected in lysates from COS7,
as well as in murine cells (which lack the upstream start
methionine), suggest a heavy post-translational modiﬁcation,
which merits further investigation.
GORAB was classiﬁed as a golgin with predicted coiled-
coil elements in the identiﬁed RAB6-binding domain
(Hennies et al., 2008). Coiled-coil domains are structural
elements found in a variety of proteins with functions ranging
from components of the extracellular matrix to transcription
factors (Qin et al., 2004). They are important structural
features as they form rigid rods giving the respective
parts of the protein an elongated shape. Coiled-coil domains
are also known as hubs for protein–protein interaction,
mediating, for example, the dimerization of basic leucine-
zipper transcription factors. Typically, golgins are rather large
proteins that are extending from the Golgi membranes, for
example, to perform vesicle tethering (Barr and Short, 2003).
For GORAB, two or three coiled-coil domains are predicted to
reside between residues 120 and 300. For comparison, in the
giantin protein, coiled-coil domains are contained in a stretch
of more than 3,000 aas. Thus, for the rather small golgin
GORAB to perform a tethering function, the ability to form
multimers would be favorable. We showed that high levels of
overexpression induce the formation of GORAB-positive
ﬁbrous structures reminiscent of ﬁbers formed when inter-
mediate ﬁlaments are highly expressed (Singh et al., 2003).
Indeed, the ﬁbers formed by GORAB overexpression also
showed staining for vimentin, possibly owing to unspeciﬁc
aggregation of the coiled-coil domains. We are aware that
mislocalization of overexpressed proteins is a problem for
biochemical interaction experiments. Therefore, we used
endogenous GORAB protein for in vitro pulldown assays
whenever possible and made sure that overexpressed FLAG-
tagged GORAB behaved identically. Colocalization studies
were performed as shortly after transfection as possible, and
only cells with low expression levels without ﬁbrous artifacts
were included. The highly conserved IGRAB domain deﬁned
in this study is reminiscent of the GRIP domain of certain
trans-golgins (Munro and Nichols, 1999), although it is not
found at the C terminus, but in the protein’s center. Although
most mutations found in GO entail a loss of the protein, both
missense mutants studied here were stable, but altered the
binding of the IGRAB domain to RAB6 and ARF5 to different
degrees. In GORAB p.Ala220Pro, the exchange of the ﬂexible
aa alanine to proline is likely to stiffen the polypeptide
backbone, thereby disrupting the IGRAB structure. In GORAB
p.Ser175Phe, the exchange of a small for a bulky aa could
interfere with the tight packing of the coils. The fact that
patients with these mutations showed the typical GO
phenotype indicate that the effects must be of comparable
severity to the complete protein loss (Al-Dosari and Alkuraya,
2009; Gardeitchik et al., 2014).
Taken together, we have shown that GORAB is a mainly
trans-Golgi-localized protein that interacts with Rab6 and the
previously unreported interaction partner ARF5 through its
IGRAB domain. Analysis of two missense mutations in the
IGRAB domain suggests that loss of proper Golgi targeting of
GORAB is a central aspect of the GO pathomechanism.
MATERIALS AND METHODS
Cell culture and drug treatment
HeLa cells were kept in DMEM (Life Technologies, Darmstadt,
Germany) supplemented with 5% fetal calf serum (Gibco, Life
Technologies, Darmstadt, Germany) and 1% Ultraglutamine (Life
Technologies) at 37 °C, 5% CO2. Primary skin ﬁbroblasts were
cultured in alpha Modiﬁed Eagle’s Medium (Life Technologies)
supplemented with 10% fetal calf serum (Gibco), 1% Ultraglutamine
(Invitrogen), and 1% Penicillin/Streptomycin (Life Technologies) at
37 °C, 5% CO2. For drug treatment, cells were incubated with
normal growth medium supplemented with 5mgml− 1 BFA (Sigma-
Aldrich, Munich, Germany) or 33 μM Nocodazole (Sigma-Aldrich) for
the indicated time.
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Constructs and plasmids
For transient transfection of mammalian cells, the respective DNAs
were ampliﬁed from HeLa or skin ﬁbroblast cDNA and cloned into
pEGFPC2, pEGFPN3, or pFLAG-CMV-5a (all Life Technologies),
respectively, by restriction digestion and ligation. Point mutations
were introduced by overlap PCR with primers containing the
respective base exchange. Bacterial expression was performed in
the pFAT2 (modiﬁed pGAT2) vector. Y2H vectors were pFBT9
(modiﬁed pGBT9) and pAct2 (Clontech, Takara Bio, Saint-Germain-en-
Laye, France).
Transient transfection of plasmid DNA
Cells were transfected 24 hours after passage with JetPei (Polyplus-
Transfection, Illkirch, France) by a modiﬁed supplier’s protocol. For
15-cm dishes, 940 μl of 0.9% NaCl solution was mixed with 15 μg of
DNA and 30 μl of JetPei and added to 10ml of standard growth
medium. For one 6-well plate, 94 μl of 0.9% NaCl solution was mixed
with 3 μl of JetPei and 1.5 μg of DNA and added to a volume of 1ml of
standard growth medium. Cells were processed 15–18 hours later.
RNA interference
siRNA oligos against GORAB (5′-ccaugauggucacaacaautt-3′), RAB6
(5′-ucuggugaucaaagaugucuu-3′), and ARF5 (5′-uuacuguccaccaca
aagatg-3′) and a negative control siRNA oligo as nontargeting control
(Life Technologies) were transfected with INTERFERin (PolyPlus)
according to a modiﬁed supplier’s protocol. Cells were grown for
14 hours at a low density before being transfected. A volume of 90 μl
of OptiMEM (Gibco) was mixed with 10 μl of siRNA oligo at a
working dilution of 2 μM concentration and 3 μl of INTERFERin,
incubated for 10minutes and then added to 1ml of fresh standard
growth medium for transfection of one well in a six-well plate. Cells
were analyzed after 72 hours. Knockdown efﬁciency was tested by
immunoﬂuorescence, western blotting, or quantitative PCR.
Quantitative PCR
We prepared RNA using the Trizol method (Life Technologies).
A measure of 1 μg of RNA was reverse-transcribed using the Revert-
Aid kit (Fermentas, Thermo Scientiﬁc, Dreieich, Germany). The qPCR
was performed with Evagreen (Solis Biodyne, Tartu, Estonia),
using speciﬁc primers for ARF5, GORAB, RAB6, and GAPDH as
endogenous control. Sequences are available on request.
Antibodies
We used a polyclonal rabbit GORAB antibody as described before
(Hennies et al., 2008). Mouse anti-COPI antibody was a kind gift
from F.T. Wieland and V. Popoff. The following commercially
available antibodies were used: GM130 (BD Biosciences, Heidel-
berg, Germany), RAB6 (C-19, Santa Cruz Biotechnology, Heidelberg,
Germany), giantin (Serotec, Puchheim, Germany), GORAB (Sigma-
Aldrich), GS15 (BD Biosciences), p230 (BD Biosciences), vimentin
(Millipore, Schwalbach, Germany), FLAG M2 (Sigma-Aldrich), FLAG
(Rabbit; Sigma-Aldrich), and actin (Sigma-Aldrich). Secondary anti-
bodies were Alexa 488- and Alexa 555-labeled (Life Technologies) or
HRP-labeled antibodies (Cell Signaling Technology, New England
Biolabs, Frankfurt, Germany).
Y2H interaction study
For Y2H experiments, PJ69-4A yeast was transformed with bait and
prey plasmids and grown on SC-Leu/-Trp medium plates. Colonies
were picked and restreaked on quadruple dropout medium plates
(SC-Leu/-Trp/-His/-Ade) and grown for another 2–3 days at 30 °C.
Growth on selective medium indicates interaction.
Immunoﬂuorescence microscopy
Cells were ﬁxed with 4% paraformaldehyde and permeabilized with
0.1% Saponin in 3% bovine serum albumin/phosphate-buffered
saline. Primary antibody incubation was performed overnight
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at 4 °C. Secondary antibodies were applied for 1–2 hours at room
temperature. Nuclei were labeled with 4’,6-Diamidin-2-phenylindol
(Life Technologies). Cells were mounted and imaged with a Zeiss
LSM510 Lasermodule and Axiovert 200M system and the Zen2009
software (Zeiss, Oberkochen, Germany).
In vitro pulldown assays
In vitro pulldown assays were performed according to Christoforidis
and Zerial, 2000. In short, bacterially expressed and puriﬁed
glutathione S-transferase-tagged ARF5 or RAB6 were coupled to
Glutathione-S-Sepharose (Thermo Fisher Scientiﬁc, Dreieich,
Germany), washed with NE100 buffer (20 mM Hepes/NaOH pH
7.5, 100mM NaCl, 5 mM EDTA, 0.1% Triton X-100), and afterward
loaded with either GTP or GDP (both Sigma-Aldrich) in NL100 buffer
(20 mM Hepes/NaOH pH 7.5, 100mM NaCl, 10 mM MgCl2, 0.1%
Triton X-100) supplied with 100 μM nucleotide. HeLa cells were
transfected 16–18 hours before with the respective FLAG-tagged
construct, pelleted, and lysed in NL100 buffer supplemented with
5mM β-Mercaptoethanol and Complete protease inhibitor (Roche,
Mannheim, Germany) for 15minutes on ice. Cell debris was
removed by centrifugation, and the HeLa lysate was incubated for
1–2 hours with the bead-coupled GTPases. After washing three times
with lysis buffer, beads were boiled in SDS-PAGE loading buffer and
fractions were analyzed by western blotting by loading 5% of input
and 50% of pulldown fraction.
Immunoprecipitation
Hela cells were resuspended in modiﬁed RIPA buffer (Tris-HCl:
50mM, pH 7.4, NP-40: 1%, Na-deoxycholate: 0.25%, NaCl:
150mM, EDTA: 1mM, Inhibitor Cocktail (Sigma-Aldrich)) and
incubated at 4 °C for 20minutes to lyse cells followed by
centrifugation. The supernatant was incubated with protein A/G
agarose (Thermo Fisher Scientiﬁc) for 10 minutes on a roller. Beads
were removed by centrifugation. To the precleared lysate, GORAB
antibody (Sigma-Aldrich HPA027208, 1:200) was added and
incubated overnight at 4 °C. The immunocomplex was captured by
adding Protein A/G agarose beads and by incubation on a roller for
1 hour. Beads were washed once with modiﬁed RIPA buffer and
three times with 50mM ammoniumbicarbonate (pH 8.0), followed by
elution with 1% formic acid. Eluated fractions were analyzed by
mass spectrometry.
Mass spectrometry analysis
IP samples were reduced by a ﬁnal concentration of 50 mM DTT and
incubated for 1 hour at 56 °C. After alkylation, samples were
precipitated by ice-cold (−20C°) acetone overnight, dissolved in
50mM NH4HCO3, and digested with 0.5 μg of trypsin at 37C° ON.
The digests were desalted by C18 stage Tips and dissolved in 5%
acetonitrile and 2% formic acid before LC-MS analysis. Nano liquid
chromatography, online coupled to a Linear Ion Trap (LTQ)-Orbitrap
XL mass spectrometer (Thermo-Electron, Karlsruhe, Germany), was
used to sequence peptides eluting from a PicoFrit analytical column
(New Objectives, Woburn, MA) with 3-μm C18 resin (Reprosil-AQ
Pur, Dr Maisch, Ammerbuch-Entringen, Germany). A nonlinear
gradient from 2 to 40% solvent B over 160minutes at a ﬂow rate of
200 nl min−1 (solvent A: 97.9% H2O, 2% acetonitrile, 0.1% formic
acid; solvent B: 97.9% acetonitrile, 2% H2O, 0.1% formic acid) was
used. A voltage of 1.8 kV was applied for nanoelectrospray generation.
A cycle of one full FT scan mass spectrum (300− 2,000m/z,
resolution of 60,000 at m/z 400) was followed by 10 data-
dependent MS/MS scans acquired in the linear ion trap with
normalized collision energy (setting at 35%). MaxQuant v1.4.1.2
(Martinsried, Germany) was used for data processing.
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